Afamitresgene autoleucel
Products billed under this code include Tecelra.
Payment limit per PER THERAPEUTIC DOSE, by effective quarter, 3Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Tecelra.
Payment limit per PER THERAPEUTIC DOSE, by effective quarter, 3Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tecelra | USWM, LLC | 83205-0001-02 | 1 | $813,967.375 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $813,967.375 | $0.00 | PER THERAPEUTIC DOSE | Afamitresgene autoleucel | v1, posted September 17, 2026 |
| 3Q26 | $813,967.375 | +$43,347.375 | PER THERAPEUTIC DOSE | Afamitresgene autoleucel | v1, posted September 15, 2026 |
| 2Q26 | $770,620.00 | $0.00 | PER THERAPEUTIC DOSE | Afamitresgene autoleucel | v1, posted September 15, 2026 |
| 1Q26 | $770,620.00 | $0.00 | PER THERAPEUTIC DOSE | Afamitresgene autoleucel | v1, posted September 15, 2026 |
| 4Q25 | $770,620.00 | $0.00 | PER THERAPEUTIC DOSE | Afamitresgene autoleucel | v1, posted September 8, 2026 |
| 3Q25 | $770,620.00 | – | PER THERAPEUTIC DOSE | Afamitresgene autoleucel | v1, posted March 10, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.